
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at having axitinib before surgery for kidney cancer to help shrink the cancer or stop it growing. It is open to people who can have surgery to remove all, or part, of their cancer.
Axitinib (Inlyta) is a targeted cancer drug called a tyrosine inhibitor. It works by blocking certain proteins called tyrosine kinases that signal the cancer cell to grow.
Previous studies suggest that tyrosine inhibitors might slow, or stop the growth of cancers. It might also reduce the size of the cancer.
At the moment axitinib is used after surgery for kidney cancer that has spread to another part of the body. In this study researchers want to know if having axitinib before surgery can stop the cancer from growing or shrink the cancer. This could then reduce the amount of surgery you need to remove the kidney cancer.
Everyone in this study will take axitinib for a short time before their surgery.
The main aim of this study is see if axitinib can stop kidney cancer from growing or shrink it before having surgery.
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
You may be able to join this study if all of the following apply. You:
You cannot join this study if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
This is a phase 2 study. The study team need 20 people to join.
Everyone takes axitinib for 8 weeks before surgery. You have your surgery during week 9.
Axitinib is a tablet you take twice a day. Your doctor will tell you how many to take. After 2 weeks your doctor might increase your dose if you don’t have any bad side effects.
Samples
You have a sample of tissue (biopsy) done between 1 and 4 weeks before starting axitinib. This to find if you able to join the study.
At the same time the team will take 4 extra samples of tissue.
The team will also take an extra blood sample and urine sample:
They will use these samples and the tissue samples to:
You don’t have to agree to give these extra samples. You can still take part in the main study.
You see the doctor to have some tests before taking part. These tests include:
A week before starting treatment you see the doctor to have:
You see the doctor every 2 weeks during treatment for the same tests.
Everyone has an MRI scan in the 3rd week. People whose cancer hasn’t spread will also have CT scan at this time.
Everyone has a CT scan in the week of surgery.
After surgery you see the doctor at 6 weeks and 12 weeks for:
Your doctor will then tell you how often they want to see you after this.
The common side effects of axitinib are:
We have more information about axitinib.
Your doctor will talk to you about the side effects before you agree to take part in the study.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Mr Grant Stewart
Common Services Agency (CSA)
NHS National Services Scotland
Pfizer
Scottish Clinical Trials Research Unit (SCTRU)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”